Infection and inflammation
In infectious and inflammatory diseases, Finnish research expertise is strongest in the development of diagnostics methods and research on certain common diseases.
The National Institute of Health and Welfare, several research groups in all Finnish biocentres, innovative biotech companies, diagnostic and vaccine companies in particular, and large pharmaceutical corporations do research on the prevention, diagnosis and treatment of infectious and inflammatory diseases.
Biotie Therapies Corporation is developing a VAP-1 antibody for inflammatory diseases, Faron Pharmaceuticals Ltd an anti-Clever-1 antibody to prevent inflammation and the spread of cancer and Laurantis Pharma Oy a cis-urocanic acid for atopic dermatitis.
In Finland, the eradication of infectious diseases is supported by the advanced child welfare clinic system and its extensive preventative vaccination programme. At the moment, Finnish research is focusing on the development of serology and the immunogenetics of bacterial infections.
Another area of focus is the link between certain infectious and common diseases, for example enteroviruses and type 1 diabetes. Research on IBD (inflammatory bowel disease) and the link between intestinal bacteria and the central nervous system are also areas of great interest.
Several Finnish diagnostic companies, especially ones in Helsinki and Turku, are developing innovative diagnostic technologies for severe infectious diseases. These companies include Abacus Diagnostica Ltd, ArcDia Group, Mobidiag Ltd and PerkinElmer Finland Oy.
The following links include some examples of organizations with infectious and inflammatory disease expertise in Finland: